About Us

Until recently, Sunshine Biopharma has been operating as a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following the Company’s recent entry and expansion into the generic pharmaceuticals business, Sunshine Biopharma has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.

Generic Pharmaceuticals Operations

Sunshine Biopharma operates a wholly owned Canadian subsidiary dedicated to conducting generic pharmaceuticals business in Canada and elsewhere around the globe. Sunshine recently signed Cross Referencing Agreements with a major pharmaceutical company for four prescription generic drugs which Sunshine will sell under its own “SBI” label as follows:

  • SBI-Anastrozole for treatment of Breast Cancer
  • SBI-Letrozole for treatment of Breast Cancer
  • SBI-Bicalutamide for treatment of Prostate Cancer
  • SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)

Sunshine is currently in the process of securing a Drug Establishment License ("DEL") for the premises and a Drug Identification Number (“DIN”) for each of these products from Health Canada. See "Drugs on the Market".

Proprietary Drug Development Operations

Sunshine Biopharma's flagship anticancer compound is Adva-27a, a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells. These and other preclinical results have been Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012 (Publication PDF). Adva-27a is currently in the IND-Enabling stage of development. We are planning to conduct our Adva-27a Phase I Clinical Trials on Pancreatic Cancer and in parallel multidrug resistant Breast Cancer patients at McGill University's Jewish General Hospital in Montreal (Canada). The US Patent Number 8,236,935 covering Adva-27a was issued on August 7, 2012. Sunshine Biopharma is direct owner of this as well as all right, title and interest in and to all worldwide patents covering Adva-27a, including all issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029. Sunshine Biopharma has not granted any licenses or rights to any entity under these patents. See "Drugs in Development".